antibodies - online.com







SARS-CoV-2 IgG Antibody ELISA Kit

Publications



\sim	
()\/户	rview
\circ	V I C V V

Quantity:	96 tests
Target:	SARS-CoV-2 IgG Antibody
Reactivity:	Human, SARS Coronavirus-2 (SARS-CoV-2)
Method Type:	Indirect ELISA
Application:	ELISA

Product Details

Purpose:	Pre-coated ELISA kit for the qualitative detection of the COVID-19 IgG in human serum.
Sample Type:	Serum
Analytical Method:	Qualitative
Detection Method:	Colorimetric
Specificity:	This SARS-CoV-2 / COVID-19 ELISA kit is designed for the qualitative measurement of the human anti-COVID-19 IgG antibody in serum. The assay utilizes the microplate based enzyme immunoassay technique.
Characteristics:	IgG is most abundantly found immunoglobulin to be produced in response to an antigen and will be maintained in the body after initial exposure for long term response. Antibody titer is 4 times or higher than that of the acute phase. Discover all available SARS-CoV-2 / COVID-19 ELISA kits
Components:	 COVID-19 antigen coated Microplate COVID-19 IgG Sample Diluent HRP labeled Anti-hIgG Tracer Antibody

- ELISA Wash Concentrate
- · ELISA HRP Substrate
- · ELISA Stop Solution
- · COVID-19 IgG Negative Control
- COVID-19 IgG Positive Control

Material not included:

- Precision single channel pipettes capable of delivering 10 μL, 25 μL, 100 μL, and 1000 μL, etc.
- Repeating dispenser suitable for delivering 100 μL.
- Disposable pipette tips suitable for above volume dispensing.
- Disposable 12 x 75 mm or 13 x 100 glass tubes.
- · Disposable plastic 1000 mL bottle with caps.
- · Aluminum foil.
- · Deionized or distilled water.
- · Plastic microtiter well cover or polyethylene film.
- ELISA multichannel wash bottle or automatic (semi-automatic) washing system.
- Spectrophotometric microplate reader capable of reading absorbance at 450 nm.

Target Details

Target:

SARS-CoV-2 IgG Antibody

Application Details

Application Notes:

Can easily be converted to quantitative to aid in the development of IgG-based treatments for COVID-19.

Plate:

Pre-coated

Protocol:

Assay controls and 1:100 diluted human serum samples are added to the microtiter wells of a microplate that was coated with COVID-19 recombinant full length nucleocapsid protein. After the first incubation period, the unbound protein matrix is removed with a subsequent washing step. A horseradish peroxidase (HRP) labeled polyclonal goat anti-human IgG tracer antibody is added to each well. After an incubation period, an immunocomplex of "COVID-19 recombinant antigen - human anti-COVID-19 IgG antibody - HRP labeled anti human IgG tracer antibody" is formed if there is specific coronavirus IgG antibody present in the tested specimen. The unbound tracer antibody is removed by the subsequent washing step. HRP tracer antibody bound to the well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the tracer antibody bound to the anti-COVID-19 IgG on the wall of the microtiter well is proportional to the amount of the anti-COVID-19 IgG antibody level in the tested specimen.

Application Details

Restrictions:

For Research Use only

Handling

Storage:

4°C

Storage Comment:

This test kit must be stored at 2 - 8°C upon receipt. For the expiration date of the kit refer to the label on the kit box. All components are stable until this expiration date.

Publications

Product cited in:

Ahn, Sohn, Lee, Cho, Hyun, Baek, Jeong, Kim, Ku, Yeom, Roh, Ahn, Chin, Kim, Lee, Yong, Kim, Kim, Choi: "Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea." in: **Journal of Korean medical science**, Vol. 35, Issue 14, pp. e149, (2020) (PubMed).

Krüttgen, Cornelissen, Dreher, Hornef, Imöhl, Kleines: "Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG." in: **Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology**, Vol. 128, pp. 104394, (2020) (PubMed).

Fallet, Kyburz, Walker: "Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B-cells due to treatment with rituximab." in: **Arthritis & rheumatology (Hoboken, N.J.)**, (2020) (PubMed).

Egger, Bundschuh, Wiesinger, Gabriel, Clodi, Mueller, Dieplinger: "Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma." in: **Clinica chimica acta; international journal of clinical chemistry**, Vol. 509, pp. 18-21, (2020) (PubMed).

Whittaker, Bamford, Kenny, Kaforou, Jones, Shah, Ramnarayan, Fraisse, Miller, Davies, Kucera, Brierley, McDougall, Carter, Tremoulet, Shimizu, Herberg, Burns, Lyall, Levin: "Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2." in: **JAMA**, (2020) (PubMed).

There are more publications referencing this product on: Product page